PCI Synthesis establishes a cGMP Advanced Polymer Development and Manufacturing Group

Published: 21-Apr-2016
Manufacturing

The team has experience with developing polymeric materials for implantable medical devices, drug delivery technologies, therapeutics, excipients and medical grade coatings


US firm PCI Synthesis has formed a cGMP Advanced Polymer Development and Manufacturing Group, which is currently developing and manufacturing more than a dozen advanced polymer-based projects.

The independent cGMP contract manufacturing organisation (CMO), which is based in Newburyport, MA, says the addition of an advanced polymer-based materials development and manufacturing capability significantly expands its customer base and reach within this growing market.

The team currently includes polymer chemists with expertise in the development, scale up, and cGMP manufacturing of these materials. The team is also supported by PCI Synthesis’s existing Kilo Lab team.

Products in development include a broad range of polymer-based materials, including: implantable medical devices including biodegradable implants; nano-polymer particle technology; combination API and polymer technologies; drug delivery technologies; therapeutics and excipients and medical grade coatings.

The new Advanced Polymer Manufacturing Group operates out of the company’s development lab in Devens, MA, and collaborates with PCI Synthesis' cGMP facilities in Newburyport.

  • Companies:
  • Seqens
See more

You may also like

Manufacturing

Seqens isopropanol plant expansion

Read more
The plant has almost been completed and is due to be finalised as planned by end of Q1 2022

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer Denis will be responsible for optimising global operations for the company
  3. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  5. Degassers for fluidic applications The range employs a constant vacuum degassing system and can deal with a wide range of flow rates

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Seqens isopropanol plant expansion

The plant has almost been completed and is due to be finalised as planned by end of Q1 2022
Manufacturing

PCI Synthesis obtains DEA registration for controlled substance development and manufacturing

Certification expands the company's capabilities to handle cGMP development for schedule II, III, IV and V
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Initiating change in drug development and manufacture

With R&D and production costs spiralling and the growing regulatory requirements biting into the profit margins of drug sales, the industry needs radical change to manufacturing models, argues Ed Price, President, PCI Synthesis
Manufacturing

PCI Synthesis earns top Life Science Leader awards for second year in a row
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

GDUFA – the promise and the reality

The introduction of GDUFA was meant to reduce a regulatory backlog and improve patient safety. Edward Price, President, PCI Synthesis, argues it has, in fact, had a more far-reaching impact
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Manufacturing

INEOS Nitriles launches INVIREO - the first bio-based acetonitrile

The company has released INVIERO, an acetonitrile capable of significantly reducing the carbon footprint of manufacturing processes
Subscribe now